2 replies to this topic

[malbecman]

I (my university) does not have a subscription to this journal and I'm not sure if I want to purchase the article, eg, will it tell me anything new? Anyone else read it? Is it worth it?

Thanks!

Current Opinion in Investigational Drugs 2008 Apr;9(4):371-8.
Sirtuins: Novel targets for metabolic disease.
Elliott PJ, Jirousek M. Sirtris Pharmaceuticals Inc, 200 Technology Square, Cambridge, MA 02139, USA. Email: pelliott@sirtrispharma.com.

Sirtuins represent a novel family of enzymes that are collectively well situated to help regulate nutrient sensing and utilization, metabolic rate and ultimately metabolic disease. Activation of one of these enzymes, SIRT1, leads to enhanced activity of multiple proteins, including peroxisome-proliferator activated receptor coactivator-1alpha (PGC-1alpha), which helps to mediate some of the in vitro and in vivo effects of sirtuins. As such, enhanced SIRT1 activity decreases glucose levels, improves insulin sensitivity, increases mitochondrial number and function, decreases adiposity, improves exercise tolerance and potentially lowers body weight. SRT-501 is a proprietary formulation of resveratrol with improved bioavailability. As such, SRT-501 represents the first in a novel class of SIRT1 activators that has proven to be safe and well-tolerated in humans. Clinical trials in type 2 diabetic patients are currently underway.

PMID: 18393104

http://www.biomedcen...ninvestigdrugs/

[edward]

It looks like the article is just going to summarize what is currently going on in the field of sirtuins to give the readers of the journal an update/overview. I don't think there will be anything too exciting in the article. The journal itself though looks pretty cool as quick up date of what is going on in areas that I personally and probably people on this board are interested in... to bad its not free.

[malbecman]

Ok, that was my take-likely nothing really new but a good summary article. At least all federally funded research will soon have the requirement of being publically accessible. It wont stop private companies and journals from charging for reading but should help swing the door more open.........

It looks like the article is just going to summarize what is currently going on in the field of sirtuins to give the readers of the journal an update/overview. I don't think there will be anything too exciting in the article. The journal itself though looks pretty cool as quick up date of what is going on in areas that I personally and probably people on this board are interested in... to bad its not free.